Inactive Instrument

Teligent

Equities

TLGT

US87960W2035

TELIGENT, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)

December 10, 2020 at 04:17 pm EST

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or


             Standard; Transfer or Listing.

On December 4, 2020, Teligent, Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market ("Nasdaq") informing the Company that for the last 30 consecutive business days, the bid price of the Company's securities had closed below $1.00 per share, which is the minimum required closing bid price for continued listing on Nasdaq pursuant to Listing Rule 5450(a)(1) (the "Bid Price Requirement").

The Notice has no immediate effect on the Company's Nasdaq listing or trading of the Company's common stock. The Company has 180 calendar days, or until June 2, 2021, to regain compliance. To regain compliance, the closing bid price of the Company's securities must be at least $1.00 per share for a minimum of ten consecutive business days. If the Company does not regain compliance by June 2, 2021, the Company may be eligible for additional time to regain compliance or if the Company is otherwise not eligible, the Company may request a hearing before a Hearings Panel.

As previously disclosed, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Filing Requirement") as a result of the Company not having timely filed its Quarterly Report on Form 10-Q for the three months ended September 30, 2020 ("Form 10-Q") with the Securities and Exchange Commission (the "SEC"). With respect to the Filing Requirement, the Company has until January 25, 2021 to submit a plan to Nasdaq to regain compliance under the Nasdaq's listing rules.

Also, as previously disclosed, the Company is not in compliance with Nasdaq Listing Rule 5450(b)(3)(C) because the Company failed to maintain a minimum market value of publicly held shares of $15 million for 30 consecutive days (the "MVPHS Requirement"). If the Company also does not regain compliance by January 25, 2021 with respect to the MVPHS Requirement, then Nasdaq will notify the Company that the Company's common stock will be delisted from the Nasdaq Global Market, unless the Company requests a hearing before a Nasdaq Hearings Panel.

Latest news about Teligent

Teligent, Inc. Went Out of Business	22-07-26	CI
Second Amended Liquidation Plan Approved for Teligent, Inc.	22-07-15	CI
Second Motion for Exclusivity Period Extension Approved For Teligent, Inc.	22-05-25	CI
Second Amended Joint Liquidation Plan Filed by Teligent, Inc.	22-05-24	CI
First Amended Disclosure Statement Approved for Teligent, Inc.	22-04-29	CI
First Amended Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	22-04-27	CI
Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	22-04-08	CI
First Motion for Exclusivity Period Extension Approved For Teligent, Inc.	22-02-28	CI
Motion for Case Conversion Filed by Teligent, Inc.	22-02-22	CI
First Motion for Exclusivity Period Extension Filed by Teligent, Inc.	22-02-09	CI
Hikma Pharmaceuticals Closes $46 Million Purchase of Teligent's Canadian Assets	22-02-03	MT
Pharmaceutical Associates, Inc. completed the acquisition of Generic and Branded US Marketing Authorizations of Teligent, Inc. (OTCPK:TLGT.Q).	22-02-02	CI
Hikma Pharmaceuticals PLC completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).	22-02-02	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-19	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-19	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-18	CI
London Shares to Open Higher as Traders Focus On Key Data	22-01-17	DJ
Hikma Pharmaceuticals to Enter Canadian Market With $46 Million Asset Acquisition	22-01-17	MT
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Hikma Pharmaceuticals PLC agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million.	22-01-16	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-14	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-13	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-13	CI

Chart Teligent

Duration

Period

More charts

Company Profile

Teligent, Inc. is a generic pharmaceutical company. The Company is focused on the development, manufacturing and marketing of a portfolio of generic pharmaceutical products under its own label and private label for other pharmaceutical companies in topical, injectable, complex and other dosage forms. It also provides contract development and manufacturing services to the prescription and over-the-counter (OTC) pharmaceutical and cosmetic markets. Under the Company's own label, it markets and sells generic topical, and generic and branded generic injectable pharmaceutical products in the United States. In the United States, the Company markets approximately 37 generic topical pharmaceutical products and one branded injectable pharmaceutical product. The Company's portfolio of hospital-based sterile injectable products, including cephalosporins, Cefotan (Cefotetan for Injection), Fortaz (Ceftazidime) and Zinacef (Cefuroxime Sodium).

Sector

More about the company